<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Evaluation of patients with polyuria</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Evaluation of patients with polyuria</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Evaluation of patients with polyuria</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel G Bichet, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Sterns, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Emmett, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION AND DEFINITION</span><span class="headingEndMark"> — </span>Polyuria has generally been defined as a urine output exceeding 3 L/day in adults and 2 L/m<sup>2</sup> in children. It must be differentiated from the more common complaints of frequency or nocturia, which may not be associated with an increase in the total urine output.</p><p>The evaluation of patients with polyuria is discussed in this topic. The causes, clinical manifestations, and treatment of polyuria due to <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> deficiency (AVP-D; previously called central diabetes insipidus) or arginine vasopressin resistance (AVP-R; previously called nephrogenic diabetes insipidus) are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2373.html" rel="external">"Arginine vasopressin deficiency (central diabetes insipidus): Etiology, clinical manifestations, and postdiagnostic evaluation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2289.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Clinical manifestations and causes"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2313.html" rel="external">"Arginine vasopressin deficiency (central diabetes insipidus): Treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2382.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Treatment"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">CAUSES OF POLYURIA</span><span class="headingEndMark"> — </span>Polyuria may be caused by a solute (osmotic) diuresis or a water diuresis  (<a class="graphic graphic_table graphicRef119681" href="/d/graphic/119681.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef119721" href="/d/graphic/119721.html" rel="external">algorithm 1</a>). (See <a class="local">'Solute (osmotic) diuresis'</a> below and <a class="local">'Water diuresis'</a> below.)</p><p>The most common cause of an osmotic diuresis is glucose-induced diuresis in patients with uncontrolled diabetes mellitus. Three other major causes of polyuria are all due to water diuresis, in which large volumes of dilute urine (urine osmolality usually below 250 mosmol/kg) are excreted: primary polydipsia, which is primarily seen in adults and adolescents; <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> deficiency (AVP-D; previously called central diabetes insipidus); and arginine vasopressin resistance (AVP-R; previously called nephrogenic diabetes insipidus) [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3278429927"><span class="h2">Solute (osmotic) diuresis</span><span class="headingEndMark"> — </span>In some patients with polyuria, particularly of acute onset, the increase in urine output may be due to a solute or osmotic diuresis in which the primary abnormality is an inability to reabsorb a substantial proportion of the filtered solute  (<a class="graphic graphic_table graphicRef119681" href="/d/graphic/119681.html" rel="external">table 1</a>).</p><p>Major causes of polyuria due to a solute diuresis include:</p><p class="bulletIndent1"><span class="glyph">●</span>Glucosuria – Glucosuria usually results from hyperglycemia in patients with diabetes mellitus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urea diuresis – A urea diuresis most often occurs in patients with resolving acute kidney injury.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sodium diuresis – A sodium diuresis is usually caused by administration of large volumes of intravenous <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> or after relief of bilateral urinary tract obstruction.</p><p></p><p class="headingAnchor" id="H3201025388"><span class="h3">Glucosuria (usually due to hyperglycemia)</span><span class="headingEndMark"> — </span>Glucosuria, usually due to uncontrolled diabetes mellitus, is the major cause of an osmotic diuresis in outpatients. In addition, inpatients with severe AVP-D who are treated with large volumes of <a class="drug drug_general" data-topicid="8711" href="/d/drug information/8711.html" rel="external">intravenous dextrose</a> and water can develop hyperglycemia, glucosuria, and polyuria that is antidiuretic hormone (ADH) resistant. (See  <a class="medical medical_review" href="/d/html/2313.html" rel="external">"Arginine vasopressin deficiency (central diabetes insipidus): Treatment"</a>.)</p><p>Glucosuria can also develop in patients with diabetes treated with sodium-glucose cotransporter 2 inhibitors. These drugs inhibit renal glucose absorption and produce glucosuria and an osmotic diuresis [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/109245.html" rel="external">"Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H232583011"><span class="h3">Other causes of solute diuresis</span><span class="headingEndMark"> — </span>Aside from glucosuria, other causes of solute diuresis are:</p><p class="bulletIndent1"><span class="glyph">●</span>Urea diuresis – Polyuria due to a urea diuresis (in which urea acts as an osmotic agent) may develop in several settings. Large amounts of urea may be derived from:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Resolution from azotemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Administration of urea as therapy in patients with hyponatremia [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/2357.html" rel="external">"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat", section on 'Urea'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tissue catabolism (eg, due to glucocorticoid therapy). Lean body tissues are approximately 20 percent protein by weight, and protein catabolism results in the production of urea.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Administration of high amounts of protein orally, via feeding tube, or intravenously, which will be catabolized to urea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sodium diuresis – Volume expansion due, for example, to large volumes of intravenous <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> or to the release of bilateral urinary tract obstruction may produce a sodium diuresis and polyuria [<a href="#rid1">1,4-6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mannitol – <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">Mannitol</a>, which is usually given to treat increased intracranial pressure, can induce an osmotic diuresis and polyuria. (See  <a class="medical medical_review" href="/d/html/2333.html" rel="external">"Complications of mannitol therapy"</a>.)</p><p></p><p>Polyuria in which there is a marked increase in sodium excretion (ie, sodium salts make up most of the increased solute excretion) is almost always <strong>appropriate</strong>, resulting from volume expansion induced either by <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> loading or, following relief of urinary obstruction, by fluid retained during the period of obstruction [<a href="#rid5">5,6</a>]. In addition to the excretion of retained sodium, increased urea excretion can contribute to a postobstructive diuresis when urea has also been retained as evidenced by a substantial increase in blood urea nitrogen. (See  <a class="medical medical_review" href="/d/html/7174.html" rel="external">"Clinical manifestations and diagnosis of urinary tract obstruction (UTO) and hydronephrosis", section on 'Prognosis'</a>.)</p><p>Many clinicians faced with a urine output that may initially exceed 1000 mL per hour in adults feel compelled to replace the urine output with intravenous fluids. This will only prolong the polyuria driven by increased sodium excretion since volume expansion will persist. Optimal therapy of a postobstructive diuresis consists of fluid infusion at a maintenance level, such as 75 mL of one-half isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> per hour. The development of volume depletion, as evidenced by hypotension or a rise in the blood urea nitrogen, is unusual with this regimen [<a href="#rid5">5,6</a>].</p><p>An exception to this general rule can occur in infants with congenital obstructive uropathy in whom the associated ADH resistance is sufficiently severe that the maximum urine osmolality is well below that of the plasma. In these infants, relief of the obstruction can lead to a marked water diuresis with subsequent hypernatremia [<a href="#rid7">7,8</a>]. Following relief of obstruction, fluid status should be carefully monitored and fluid therapy adjusted as necessary.</p><p>It is possible that some of these patients have congenital nephrogenic DI, with polyuria, not obstruction, being responsible for urinary tract and bladder dilation. This is also called flow uropathy, which was observed in 38 percent of cases in a cohort of 315 patients with congenital AVP-R [<a href="#rid9">9-12</a>]. (See  <a class="medical medical_review" href="/d/html/2382.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Treatment"</a>.)</p><p class="headingAnchor" id="H1312525735"><span class="h3">Not causes of true polyuria: Salt wasting and typical diuretic use</span><span class="headingEndMark"> — </span>As a general rule, underlying kidney disease can impair sodium conservation in the presence of volume depletion. However, except in rare cases of Bartter syndrome, salt-wasting nephropathies do <strong>not</strong> cause true polyuria. This is in part due to the phenomenon of tubuloglomerular feedback in which increased sodium chloride delivery to the macula densa (due to decreased reabsorption in the more proximal segments) results in afferent arteriolar constriction and a fall in glomerular filtration rate, thereby limiting the degree of sodium chloride loss  (<a class="graphic graphic_figure graphicRef73046" href="/d/graphic/73046.html" rel="external">figure 1</a>) [<a href="#rid13">13-15</a>]. (See  <a class="medical medical_review" href="/d/html/2344.html" rel="external">"Inherited hypokalemic salt-losing tubulopathies: Pathophysiology and overview of clinical manifestations", section on 'Clinical manifestations'</a>.)</p><p>In addition, sodium excretion induced by routine, chronic use of diuretic medications should not produce persistent polyuria (eg, hypertensive patients taking a thiazide or loop diuretic). Such patients who retain sodium when the effect of the diuretic dissipates may complain of nocturia as extracellular volume is redistributed during the night, but true polyuria does not result if the dose of diuretic is constant.</p><p class="headingAnchor" id="H2879808885"><span class="h2">Water diuresis</span><span class="headingEndMark"> — </span>Primary polydipsia, AVP-D, and AVP-R are associated with an increase in water output and the excretion of a relatively dilute urine (ie, water diuresis)  (<a class="graphic graphic_table graphicRef119681" href="/d/graphic/119681.html" rel="external">table 1</a>). In primary polydipsia, the polyuria is an appropriate response to enhanced water intake, whereas the water loss is inappropriate with either form of DI.</p><p class="headingAnchor" id="H3"><span class="h3">Primary polydipsia</span><span class="headingEndMark"> — </span>Primary polydipsia (sometimes called psychogenic polydipsia) is characterized by a primary increase in water intake. This disorder is most often seen in middle-aged women and in patients with psychiatric illnesses, including those taking a phenothiazine, which can lead to the sensation of a dry mouth. Primary polydipsia can also be induced by hypothalamic lesions that directly affect the thirst center, as may occur with an infiltrative disease such as sarcoidosis [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/2374.html" rel="external">"Causes of hypotonic hyponatremia in adults"</a>.)</p><p class="headingAnchor" id="H4"><span class="h3">Arginine vasopressin deficiency (AVP-D)</span><span class="headingEndMark"> — </span>AVP-D is due to deficient secretion of ADH. This condition is most often idiopathic (possibly due to autoimmune injury to the ADH-producing cells) or can be induced by trauma, pituitary surgery, or hypoxic or ischemic encephalopathy. Rare familial cases have been described [<a href="#rid16">16,17</a>]. (See  <a class="medical medical_review" href="/d/html/2373.html" rel="external">"Arginine vasopressin deficiency (central diabetes insipidus): Etiology, clinical manifestations, and postdiagnostic evaluation"</a>.)</p><p class="headingAnchor" id="H5"><span class="h3">Arginine vasopressin resistance (AVP-R)</span><span class="headingEndMark"> — </span>AVP-R is characterized by normal ADH secretion but varying degrees of renal resistance to its water-retaining effect. This problem, in its mild form, is relatively common since most patients who are older adults or who have underlying kidney disease have a reduction in maximum renal concentrating ability. This defect, however, is usually not severe enough to produce a symptomatic increase in urine output.</p><p>Symptomatic polyuria due to ADH resistance is seen primarily in four settings, all of which are discussed in detail elsewhere (see  <a class="medical medical_review" href="/d/html/2289.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Clinical manifestations and causes"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>AVP-R presenting in childhood is almost always due to inherited defects. The most common are X-linked hereditary AVP-R due to mutations in the <em>AVPR2</em> gene encoding the ADH receptor V2 and autosomal recessive and dominant AVP-R due to mutations in the aquaporin-2 (water channel) gene.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>AVP-R presenting in adults is almost always acquired with chronic <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> use and hypercalcemia being the most common causes of a defect severe enough to produce polyuria.</p><p></p><p class="headingAnchor" id="H6"><span class="h1">EVALUATION OF SUSPECTED POLYURIA</span><span class="headingEndMark"> — </span>In addition to <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> deficiency (AVP-D; formerly called central diabetes insipidus) and arginine vasopressin resistance (AVP-R; formerly called nephrogenic diabetes insipidus), a variety of conditions may result in the complaint of polyuria, including psychogenic polydipsia, prostatic hypertrophy, or osmotic diuresis (including postobstructive diuresis). (See  <a class="medical medical_review" href="/d/html/7174.html" rel="external">"Clinical manifestations and diagnosis of urinary tract obstruction (UTO) and hydronephrosis", section on 'Prognosis'</a>.)</p><p>The cause of polyuria is often suggested from the history (eg, age of onset and eliciting the possible presence of the different <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> disorders) and, rarely, by the plasma sodium concentration. Specific testing is then performed to establish the diagnosis.</p><p class="headingAnchor" id="H629681824"><span class="h2">Hyperglycemia or another obvious osmotic diuresis</span><span class="headingEndMark"> — </span>In some patients, the etiology of polyuria is clear from the history and initial laboratory testing, often making further evaluation unnecessary  (<a class="graphic graphic_algorithm graphicRef119721" href="/d/graphic/119721.html" rel="external">algorithm 1</a>) (see <a class="local">'Glucosuria (usually due to hyperglycemia)'</a> above and <a class="local">'Other causes of solute diuresis'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with diabetes with severe hyperglycemia and glucosuria have a solute (osmotic) diuresis caused by filtered glucose that is not reabsorbed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment with a sodium-glucose cotransporter 2 inhibitor can produce polyuria; glucosuria and onset after initiation of the drug are clues that the medication is responsible for the polyuria. However, the polyuric effect of this class of medication is relatively modest (eg, approximately 200 mL over six hours after a 25 mg dose of <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a>) [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment with exogenous urea or glucocorticoids (which can cause catabolism) or administration of a very high–protein diet can produce a urea diuresis and polyuria. Each gram of protein catabolized produces approximately 170 mg of urea. Thus, a protein load of 70 g (1 g/kg of body weight in a 70 kg adult) will generate approximately 11.2 g of urea nitrogen, which corresponds to approximately 400 mmol or mosmol of urea. At a typical urine osmolality of 300 to 500 mosmol/kg, an additional urea excretion of this magnitude will require an additional urine output of 0.8 to 1.3 liters. (See  <a class="medical medical_review" href="/d/html/2372.html" rel="external">"Urine output in arginine vasopressin disorders (diabetes insipidus)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administration of large volumes of <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>, typically in hospitalized patients, may produce an appropriate sodium diuresis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Release of bilateral urinary tract obstruction often results in polyuria due to excretion of retained sodium and urea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administration of <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a> to patients with increased intracranial pressure can produce an osmotic diuresis and polyuria.</p><p></p><p>If unsure, despite the history and initial laboratory testing, the presence of one of these causes of osmotic diuresis can be confirmed by measuring the urine osmolality (which is typically greater than 400 to 600 mosmol/kg in such patients) and calculating the total daily osmolar output (which should be &gt;1000 mosmol in patients with a solute diuresis)  (<a class="graphic graphic_algorithm graphicRef119721" href="/d/graphic/119721.html" rel="external">algorithm 1</a>). The total daily osmolar output is calculated as follows: </p><div class="formulaContainer"><div class="formula"><p>  Total daily osmolar output  =  Urine osmolality  x  24-hour urine volume</p></div></div><p>If the urine output is not known, it can be estimated in patients with stable glomerular filtration rate from the creatinine concentration of a spot urine sample. If the urine creatinine concentration is expressed in mg/dL and the daily urine creatinine excretion is assumed to be 1 g per day, then:</p><div class="formulaContainer"><div class="formula"><p>  Estimated daily urine output  =  100  ÷  Urine creatinine concentration (mg/dL)</p></div></div><p>If the urine output is estimated in this way, then the total daily osmolar output can be estimated by the following equation:</p><div class="formulaContainer"><div class="formula"><p>  Estimated daily osmolar output  =  Urine osmolality  x  100  ÷  Urine creatinine (mg/dL)</p></div></div><p class="headingAnchor" id="H2776440051"><span class="h2">When the cause is not obvious</span><span class="headingEndMark"> — </span>Solute diuresis is associated with an increase in urine output and the excretion of a concentrated urine. Primary polydipsia generates the appropriate excretion of dilute urine. By contrast, AVP-D and AVP-R are associated with an inappropriate increased output of relatively dilute urine.</p><p>Measurement of the plasma sodium concentration and the urine osmolality may be helpful in distinguishing among these disorders:</p><p class="bulletIndent1"><span class="glyph">●</span>A low plasma sodium concentration with a low urine osmolality (eg, less than one-half the plasma osmolality) is indicative of water overload due to primary polydipsia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A high plasma sodium concentration points toward either an osmotic diuresis or, particularly if the urine osmolality is less than the plasma osmolality, to an <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> disorder [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A normal plasma sodium concentration is not helpful in diagnosis but, if associated with a urine osmolality more than 600 mosmol/kg in a patient with polyuria, it excludes a diagnosis of an <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> disorder and indicates that the cause of polyuria is a solute (osmotic) diuresis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Total solute excretion (calculated on a 24-hour urine collection from the product of the urine osmolality and the measured [or estimated] urine volume [in liters]) is normal with a water diuresis (600 to 900 mosmol per day on a typical Western diet) but markedly increased with an osmotic diuresis. (See  <a class="medical medical_patient" href="/d/html/2181.html" rel="external">"Patient education: Collection of a 24-hour urine specimen (Beyond the Basics)"</a>.)</p><p></p><p class="headingAnchor" id="H4196867167"><span class="h3">Confirm the presence of polyuria</span><span class="headingEndMark"> — </span>In patients with suspected polyuria, 24-hour urine volume should ideally be assessed to confirm the presence of polyuria  (<a class="graphic graphic_algorithm graphicRef119721" href="/d/graphic/119721.html" rel="external">algorithm 1</a>). The urine osmolality, sodium, potassium, chloride, creatinine, urea nitrogen, and glucose should be measured in this 24-hour sample.</p><p>Polyuria has generally been defined as a urine output exceeding 3 L/day in adults and 2 L/m<sup>2</sup> in children. It must be differentiated from the more common complaints of frequency or nocturia, which are not associated with an increase in the total urine output.</p><p>However, potential problems with a timed urine collection include an incomplete collection and the necessity for multiple containers if the patient has severe polyuria. The latter can be minimized by obtaining an 8-hour rather than a 24-hour collection. Measurement of urinary creatinine excretion can help determine if the collection is complete. (See  <a class="medical medical_patient" href="/d/html/2181.html" rel="external">"Patient education: Collection of a 24-hour urine specimen (Beyond the Basics)"</a>.)</p><p class="headingAnchor" id="H3692396227"><span class="h3">Patients with a normal serum sodium</span></p><p class="headingAnchor" id="H1516956028"><span class="h4">Determining if further testing is necessary</span><span class="headingEndMark"> — </span>The first step in the evaluation of polyuric patients with a normal serum sodium is to distinguish between a solute (osmotic) diuresis and a water diuresis  (<a class="graphic graphic_algorithm graphicRef119721" href="/d/graphic/119721.html" rel="external">algorithm 1</a>).</p><p>Patients with a water diuresis should undergo water restriction or infusion of hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> to achieve a serum sodium concentration high enough (&gt;145 mEq/L but &lt;150 mEq/L) to stimulate <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> sufficiently to produce a maximally concentrated urine. (See <a class="local">'Goal of water restriction (or hypertonic saline)'</a> below.)</p><p>Once a serum sodium &gt;145 mEq/L has been achieved, there are two options to help distinguish primary polydipsia from an <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> disorder and to classify the disorder:</p><p class="bulletIndent1"><span class="glyph">●</span>Measurement of urine osmolality before and after the administration of <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a>  (<a class="graphic graphic_algorithm graphicRef131883" href="/d/graphic/131883.html" rel="external">algorithm 2</a>). This is the most common approach and what we do in our practice.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Determination of plasma copeptin or <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a>. However, reliable assays for copeptin and vasopressin are infrequently available. (See <a class="local">'Water restriction (or hypertonic saline) test'</a> below.)</p><p></p><p>Exceptions to this general rule are patients with a dilute urine (ie, urine osmolality well below that of the plasma) who are strongly suspected of having AVP-R (eg, long-term <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> use) and newborns and young infants who are thought to have hereditary AVP-R. In these patients who are resistant to antidiuretic hormone (ADH), the response to <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> can be evaluated without prior water restriction, which could be dangerous and induce severe hypernatremia. (See <a class="local">'Protocol in infants and children'</a> below.)</p><p>Measurements of plasma <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> or copeptin are an alternative to the assessment of the response to <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> or aqueous vasopressin. However, reliable vasopressin levels are only available in research laboratories, and reliable plasma copeptin assays are not yet available in many regions, including in the United States.</p><p>If reliable plasma copeptin assays are available, then additional methods for evaluating normonatremic patients with polyuria and a water diuresis are possible  (<a class="graphic graphic_algorithm graphicRef131884" href="/d/graphic/131884.html" rel="external">algorithm 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>If the baseline plasma copeptin is &gt;21.4 pmol/L, then the patient has AVP-R [<a href="#rid19">19</a>]. Water restriction (or hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>) is unnecessary in such cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assuming that AVP-R has been excluded, the plasma copeptin can be measured again after water restriction (or hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>), once the serum sodium is &gt;145 mEq/L; AVP-D is diagnosed if the plasma copeptin is ≤4.9 pmol/L, and primary polydipsia is diagnosed if a higher value is obtained [<a href="#rid20">20</a>]. Administration of, and judging the response to, <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> is unnecessary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Water restriction (or hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>) plus <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> administration can be avoided altogether, after exclusion of AVP-R, by measuring the plasma copeptin after infusion of <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> (0.5 g/kg over 30 minutes). Arginine provides a nonosmotic stimulus to the posterior pituitary [<a href="#rid21">21</a>]. If, at 60 minutes after infusion, the plasma copeptin is ≤3.8 pmol/L, then the diagnosis is AVP-D [<a href="#rid22">22</a>]. However, if the plasma copeptin is &gt;3.8 pmol/L, then the diagnosis is likely to be primary polydipsia (ie, with 92 percent specificity). The arginine-stimulated plasma copeptin test has not been systematically evaluated in children [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1">If suspicion for AVP-D remains high despite an arginine-stimulated plasma copeptin &gt;3.8 pmol/L, then water restriction (or hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>) plus <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> administration can be performed. (See <a class="local">'Water restriction (or hypertonic saline) test'</a> below.)</p><p></p><p class="headingAnchor" id="H537705025"><span class="h5">Urine osmolality &gt;600 mosmol/kg</span><span class="headingEndMark"> — </span>Patients with a urine osmolality &gt;600 mosmol/kg and a normal serum sodium have a solute (osmotic) diuresis. The cause of solute diuresis can often be elucidated from the history. (See <a class="local">'Solute (osmotic) diuresis'</a> above.)</p><p>Water restriction and administration of <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> are not necessary in such patients.</p><p class="headingAnchor" id="H1288471016"><span class="h5">Urine osmolality 300 to 600 mosmol/kg</span><span class="headingEndMark"> — </span>Patients with an intermediate urine osmolality of 300 to 600 mosmol/kg may have a solute diuresis, primary polydipsia, or an <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> disorder.</p><p>To determine if a solute diuresis is present, the total daily osmolar output can be calculated as the urine osmolality x the 24-hour urine volume. If the total daily osmolar output is &gt;1000 mosmol, then a solute diuresis is present. (See <a class="local">'Solute (osmotic) diuresis'</a> above.)</p><p>However, if the total daily osmolar output is &lt;900 mosmol (a normal value), then the patient has either primary polydipsia, AVP-D, or AVP-R. In such patients, the history and the response to the water restriction test can help distinguish primary polydipsia from <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> disorders and help classify the type of disorder. As noted below, hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> can be used in addition to or in place of water restriction if water restriction is unsuccessful (often in cases of primary polydipsia, partial AVP-D, or partial AVP-R) or cannot be performed. (See <a class="local">'Water restriction (or hypertonic saline) test'</a> below.)</p><p class="headingAnchor" id="H3106978211"><span class="h5">Urine osmolality &lt;300 mosmol/kg</span><span class="headingEndMark"> — </span>Polyuric patients with a low urine osmolality of &lt;300 mosmol/kg have either primary polydipsia or an <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> disorder. Most of these patients should undergo water restriction and, if necessary, administration of <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> in order to distinguish primary polydipsia from an arginine vasopressin disorder and to classify the type of disorder  (<a class="graphic graphic_algorithm graphicRef131883" href="/d/graphic/131883.html" rel="external">algorithm 2</a>). Hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> can be used in addition to or in place of water restriction if water restriction is unsuccessful (often in cases of primary polydipsia, partial AVP-D, or partial AVP-R) or cannot be performed. (See <a class="local">'Water restriction (or hypertonic saline) test'</a> below.)</p><p>However, water restriction (or hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>) may be unnecessary if the history and initial evaluation point to a particular cause of AVP-R:</p><p class="bulletIndent1"><span class="glyph">●</span>Bilateral urinary tract obstruction – Resolution of the polyuria with correction of the obstruction confirms the diagnosis of AVP-R; if obstruction is chronic, the diagnosis can be made by evaluating the response to <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> (without water restriction). (See  <a class="medical medical_review" href="/d/html/2289.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Clinical manifestations and causes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Persistent hypercalcemia – A diagnosis of AVP-R can be made by documenting the resolution of polyuria with correction of the hypercalcemia or by evaluating the response to <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> (without water restriction). (See  <a class="medical medical_review" href="/d/html/2289.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Clinical manifestations and causes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Onset of polyuria at an early age in patients with a family history of autosomal dominant or X-linked hereditary AVP-R – The diagnosis of AVP-R can be made by evaluating the response to <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> (without water restriction) or by genetic testing. (See  <a class="medical medical_review" href="/d/html/2289.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Clinical manifestations and causes", section on 'Hereditary AVP-R'</a>.)</p><p></p><p>Alternatively, plasma copeptin can be measured to diagnose AVP-R, although assays for copeptin are frequently unavailable  (<a class="graphic graphic_algorithm graphicRef131884" href="/d/graphic/131884.html" rel="external">algorithm 3</a>). Copeptin, the C-terminal glycoprotein moiety of pro-arginine <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> (AVP), is a stable surrogate marker of vasopressin secretion. Without prior water deprivation, a single baseline copeptin level &gt;21.4 pmol/L was found to differentiate AVP-R from other etiologies with 100 percent sensitivity and specificity, rendering water deprivation testing and <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> administration unnecessary [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H2881116694"><span class="h4">Water restriction (or hypertonic saline) test</span><span class="headingEndMark"> — </span>If the diagnosis is unclear, patients should be evaluated by raising the serum sodium concentration and plasma osmolality either by water restriction (supplemented by hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> if necessary) or solely by the administration of hypertonic saline. In general, we use administration of hypertonic saline only if the water restriction test is unsuccessful (often in cases of primary polydipsia, partial AVP-D, partial AVP-R) or if it cannot be performed.</p><p>Once a serum sodium &gt;145 mEq/L and serum osmolality &gt;295 mosmol/kg is attained, exogenous ADH is often given to distinguish primary polydipsia from an <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> disorder and to determine the type of disorder. <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">Desmopressin</a> is usually preferred to aqueous vasopressin because it produces fewer side effects. However, desmopressin has a longer half-life and can result in hyponatremia in patients with primary polydipsia. If there is a strong suspicion of primary polydipsia, aqueous vasopressin can be substituted for desmopressin. Desmopressin could also induce transient symptomatic hyponatremia in patients with AVP-D if a second dose is given during the same day. </p><p>Combining hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> infusion with serial measurements of copeptin (the C-terminal glycoprotein moiety of the AVP prohormone and therefore a surrogate marker of ADH) can accurately distinguish an <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> disorder from primary polydipsia [<a href="#rid20">20</a>]; provided that assays for copeptin are available, this may be performed as an alternative to judging the response to <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a>. (See <a class="local">'If water restriction is nondiagnostic'</a> below.)</p><p class="headingAnchor" id="H4050860740"><span class="h5">Goal of water restriction (or hypertonic saline)</span><span class="headingEndMark"> — </span>It is important to achieve a serum sodium concentration &gt;145 mEq/L and serum osmolality &gt;295 mosmol/kg with water restriction and/or hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> to differentiate AVP-D from primary polydipsia; simply giving exogenous ADH before the serum sodium is &gt;145 mEq/L will not distinguish between these two conditions, since both have submaximal plasma ADH levels and both will respond to <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> therapy.</p><p>Thus, we continue water restriction and/or hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> until the serum sodium concentration is &gt;145 mEq/L and serum osmolality is &gt;295 mosmol/kg or until the urine osmolality reaches a clearly normal value (ie, approximately 700 mosmol/kg or greater) [<a href="#rid24">24,25</a>].</p><p class="headingAnchor" id="H2720698255"><span class="h5">Protocol in adults and adolescents</span><span class="headingEndMark"> — </span>Our approach to the water restriction test in adults and adolescents depends upon the severity of the polyuria and the urine osmolality:</p><p class="bulletIndent1"><span class="glyph">●</span>Most patients with a urine osmolality &gt;100 mosmol/kg can safely undergo overnight fluid restriction and be evaluated the following morning. This duration of water deprivation often provides sufficient time for the plasma osmolality and serum sodium concentration to reach a level high enough (ie, 295 to 300 mosmol/kg and 145 mEq/L) to stimulate enough ADH release to maximally concentrate the urine of normal subjects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By contrast, individuals with severe polyuria and a urine osmolality &lt;100 mosmol/kg (who likely have complete AVP-D or AVP-R) should <strong>not</strong> undergo overnight water restriction. Rather, they should refrain from fluids for two to three hours prior to evaluation. In such patients, two to three hours without fluids typically provides enough time for the plasma osmolality and serum sodium concentration to increase sufficiently (ie, 295 to 300 mosmol/kg and 145 mEq/L) to stimulate enough ADH release to maximally concentrate the urine in normal subjects.</p><p></p><p class="bulletIndent1">Overnight fluid restriction should be avoided in these patients with severe polyuria since potentially severe volume depletion and hypernatremia can be induced. As an example, we saw a patient with an undiagnosed <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> disorder who was scheduled for surgery in the morning and was told to stop drinking and eating after going to sleep the night before. Surgery was cancelled when routine preoperative laboratory testing revealed a plasma sodium of 162 mEq/L.</p><p></p><p>The duration of water restriction that will be required to achieve an adequate stimulus for endogenous ADH secretion can be estimated from the patient's body weight and known hourly urine volume [<a href="#rid26">26</a>]:</p><div class="formulaContainer"><div class="formula"><p>  Hours of projected water restriction  =  Weight (kg)  x  (0.03)  x  1000 (mL)  ÷  Measured urine volume/hour (mL/hour)</p></div></div><p>When the patient is evaluated after water restriction (whether overnight or just two to three hours), the urine osmolality, plasma osmolality, and plasma sodium should be measured:</p><p class="bulletIndent1"><span class="glyph">●</span>If the urine osmolality has reached a clearly normal value (above approximately 700 mosmol/kg), this indicates that both ADH release and effect are intact and the diagnosis is primary polydipsia. Patients with partial AVP-D or partial AVP-R may have a substantial rise in urine osmolality but not to this extent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the urine osmolality is &lt;700 mosmol/kg, the plasma osmolality exceeds 295 to 300 mosmol/kg, and the plasma sodium is 145 mEq/L or higher, we administer <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> (or, less commonly, aqueous <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a>) and judge the response. The typical dose of desmopressin is 10 mcg by nasal insufflation or 2 to 4 mcg subcutaneously or intravenously. The typical dose of aqueous vasopressin is 5 units subcutaneously. (See <a class="local">'Judging the response to desmopressin'</a> below.)</p><p></p><p class="bulletIndent1">As noted above, a plasma osmolality of 295 to 300 mosmol/kg and plasma sodium of 145 mEq/L should maximally stimulate ADH release. Thus, such patients with a urine osmolality &lt;700 mosmol/kg may have either abnormal ADH release (AVP-D) or ADH effect (AVP-R).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the urine osmolality is &lt;700 mosmol/kg, the plasma osmolality is &lt;295 mosmol/kg, and the plasma sodium is &lt;145 mEq/L, we continue water deprivation and also infuse 3 percent (hypertonic) <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>, 0.1 mL/kg/min intravenously. While giving hypertonic saline, we monitor the urine osmolality and plasma sodium every hour. Ideally, two different vascular accesses should be used (one for the hypertonic saline infusion and one for plasma sodium sampling) since the hypertonic sodium infusion line will be difficult to rinse sufficiently to obtain uncontaminated, true plasma sodium measurements. We stop the infusion when the serum sodium reaches 145 mEq/L or higher or when the urine osmolality is above 700 mosmol/kg (this may take several hours):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the urine osmolality reaches a value greater than 700 mosmol/kg, then the diagnosis is primary polydipsia. Such patients are often nonadherent to fluid restriction, which can explain why they may present with a urine osmolality &lt;600 mosmol/kg and plasma osmolality &lt;295 mosmol/kg despite instructions to avoid fluids overnight.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the serum sodium reaches 145 mEq/L or higher, we administer <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> (or, less commonly, aqueous <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a>) and judge the response. The typical dose of desmopressin is 10 mcg by nasal insufflation or 2 to 4 mcg subcutaneously or intravenously. The typical dose of aqueous vasopressin is 5 units subcutaneously. (See <a class="local">'Judging the response to desmopressin'</a> below.)</p><p></p><p>The normal physiologic response to the water restriction test (or the administration of hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>) is based upon the following observations [<a href="#rid1">1,27,28</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Raising the plasma osmolality (and serum sodium concentration) leads to a progressive elevation in ADH release and an increase in urine osmolality in normal individuals  (<a class="graphic graphic_figure graphicRef65195" href="/d/graphic/65195.html" rel="external">figure 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Once the plasma osmolality reaches 295 to 300 mosmol/kg (normal 275 to 290 mosmol/kg) or the plasma sodium is 145 mEq/L or higher, the effect of endogenous ADH on the kidney is maximal. At this point, administering <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> or <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> will not further elevate the urine osmolality unless endogenous ADH release is impaired (ie, unless the patient has AVP-D).</p><p></p><p class="headingAnchor" id="H638694308"><span class="h5">Protocol in infants and children</span><span class="headingEndMark"> — </span>Water restriction is <strong>not</strong> performed in newborns or very young infants suspected to have hereditary AVP-R (eg, documented plasma sodium 145 mEq/L or higher with a concomitant urine osmolality ≤200 mosmol/kg). If the diagnosis is unclear in such patients, the preferred diagnostic test is the administration of <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> (1 mcg subcutaneously or intravenously infused over 20 minutes, maximum dose 0.4 mcg/kg of body weight) with measurement of the urine osmolality at baseline and at 30-minute intervals over the next two hours. If the urine osmolality does not increase by more than 100 mosmol/kg over baseline, the diagnosis of AVP-R is made and DNA should be obtained for mutation analysis [<a href="#rid29">29</a>]. However, the <em>AVPR2 </em>mutations (D85N, V88M, R104C, R106C, Y128S, L161P,G201D, T273M, F287L M311V, N317K N317S, N321Y, P322S, and the splice mutant c.276A&gt;G) have been associated with a mild phenotype responsive to desmopressin [<a href="#rid30">30</a>].</p><p>Water deprivation tests for older infants and children should be performed in the hospital under close medical supervision. The patient should not be allowed to lose more than 5 percent of their body weight. Monitoring of vital signs (temperature, pulse, and blood pressure), body weight, laboratory tests, urine and plasma osmolalities, and the plasma sodium concentration are essential.</p><p>A recommended protocol includes the following steps:</p><p class="bulletIndent1"><span class="glyph">●</span>The test is performed after breakfast. It is started after the child voids or, in infants, after the first spontaneous void after the morning feed. Body weight and plasma sodium and osmolality are measured after the patient voids. No further fluid is given until the test is terminated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Record each urine void and measure the urine volume and urine osmolality. Some expert centers also measure urine specific gravity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Weight and vital signs are obtained every two hours for the first four hours and then hourly. The plasma sodium and osmolality are measured at four hours and then every two hours until the conclusion of the test. There should be no delay in obtaining the results of plasma sodium and urine osmolality measurements.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The test is terminated when one of the following end points are attained:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Urine osmolality is ≥600 mosmol/kg. A urine specific gravity ≥1.020 can also indicate that urine osmolality greater than this level.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Plasma osmolality exceeds 295 or 300 mosmol/kg or plasma sodium is 145 mEq/L or higher.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The patient has lost 5 percent of body weight or exhibits signs of volume depletion.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the period of water restriction reaches six hours in infants less than six months of age, eight hours in children from six months to two years of age, or 12 hours in children older than two years of age.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At the end of the test, weight, vital signs, plasma sodium, plasma osmolality, and urine osmolality should be measured. A specimen should also be obtained for measurement of plasma ADH, which is always elevated during short dehydration tests in patients with hereditary nephrogenic DI.</p><p></p><p>Children who continue to have impaired urinary concentration (ie, urine osmolality &lt;600 mosmol/kg) despite reaching a plasma osmolality of 295 mosmol/kg or a plasma sodium of 145 mEq/L, children who lose 5 percent or more of their body weight, and if the test is terminated due to time (6 to 12 hours, depending upon the age of the child) <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> is administered (5 to 10 mcg by nasal insufflation or 2 to 4 mcg intravenously or subcutaneously). The urine volume and osmolality are then measured every 30 minutes for two hours to detect any antidiuretic response. (See <a class="local">'Judging the response to desmopressin'</a> below.)</p><p>We no longer use aqueous <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a>, which, due to its vasoconstrictive effect mediated by the V1a receptor, produces sudden and noticeable pallor that raises concerns with the caregiver.</p><p class="headingAnchor" id="H710537000"><span class="h5">Judging the response to desmopressin</span><span class="headingEndMark"> — </span>Accurate interpretation of the water restriction test usually requires that <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> <strong>not be given</strong> before the serum sodium is &gt;145 mEq/L and the plasma osmolality has reached 295 mosmol/kg. Below this level, maximum endogenous ADH effect may not be present and an antidiuretic response to exogenous ADH is of no diagnostic benefit, since it will raise the urine osmolality even in normal subjects.</p><p>After <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> administration, the urine osmolality and volume should be measured every 30 minutes over the next two hours. The two-hour monitoring period is particularly important if there is dilatation of the urinary bladder by previous high urine volumes. In this setting, any concentrated new urine might be diluted with post-micturitional residual urine (which could be as much as 200 to 400 mL).</p><p>Each of the causes of polyuria produces a distinctive pattern to water restriction and <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> administration [<a href="#rid1">1,27,28,31</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>AVP-D is usually partial, and therefore both ADH release and the urine osmolality may increase as the plasma osmolality rises but submaximally. <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">Desmopressin</a> will more than double the urine osmolality (and generate an equivalent fall in urine output) in complete AVP-D and increase the osmolality to a lesser degree in partial AVP-D [<a href="#rid27">27,28</a>].</p><p></p><p class="bulletIndent1">However, patients with partial AVP-D may be hyperresponsive to the submaximal rise in ADH induced by water restriction, perhaps due to receptor upregulation. As a result, they may be polyuric at the normal plasma osmolality of 285 to 290 mosmol/kg when ADH levels are very low but have a maximally concentrated urine at a plasma osmolality above 295 mosmol/kg when ADH levels are somewhat higher. In this setting, <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> will be without effect, resulting in a pattern suggestive of primary polydipsia [<a href="#rid28">28</a>]. The history may provide important clues in this setting, with abrupt onset favoring AVP-D and gradual onset, particularly with a history of psychiatric illness, favoring primary polydipsia. (See <a class="local">'Clues from the history'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>AVP-R is also associated with a submaximal rise in urine osmolality in response to water restriction. The elevation in plasma osmolality stimulates ADH release, which, since most patients with acquired AVP-R are partially (not completely) resistant to ADH, may induce a modest increase in urine osmolality. The administration of exogenous <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> (which increases plasma levels 5- to 10-fold) produces [<a href="#rid27">27,28</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No or minimal elevation (ie, &lt;15 percent) in urine osmolality in complete nephrogenic DI.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A small (up to 45 percent) elevation in urine osmolality in partial nephrogenic DI.</p><p></p><p class="bulletIndent2">Although the directional change in partial AVP-R is similar to that seen with partial AVP-D, the absolute numbers are quite different. Patients with the AVP-D usually achieve a urine osmolality of 300 mosmol/kg or higher after <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a>, while patients with symptomatic acquired AVP-R typically have a persistently dilute urine with an osmolality that rises, but remains well below 300 mosmol/kg, after desmopressin [<a href="#rid27">27,28</a>]. The history may also be helpful in distinguishing between these disorders. (See <a class="local">'Clues from the history'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary polydipsia will be associated with a rise in urine osmolality as the plasma osmolality is increased, usually to above 500 mosmol/kg, and no response to <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a>, since endogenous release is intact. Maximum concentrating ability is frequently impaired in this disorder, resulting in a maximum urine osmolality that may reach 500 to 600 mosmol/kg, as compared with 800 mosmol/kg or more in normal subjects. This acquired defect appears to be due to two effects of chronic polydipsia and polyuria: partial wash out the medullary interstitial gradient and downregulation of ADH release [<a href="#rid32">32</a>].</p><p></p><p>A properly performed test in which ADH is not given until the plasma osmolality exceeds 295 mosmol/kg (and the serum sodium exceeds 145 mEq/L) will usually establish the correct diagnosis.</p><p>However, distinguishing between partial AVP-D and primary polydipsia may be difficult even when the water restriction test is performed properly. If the diagnosis remains uncertain, we evaluate the response to a trial of <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> therapy. (See <a class="local">'If water restriction is nondiagnostic'</a> below.)</p><p class="headingAnchor" id="H912437299"><span class="h5">If water restriction is nondiagnostic</span><span class="headingEndMark"> — </span>The water restriction test may fail to distinguish patients with primary polydipsia from those with partial AVP-D.</p><p>If the water restriction test is nondiagnostic, we perform a therapeutic trial of <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a>, as follows. For three days, desmopressin (10 mcg intranasally) is given in the evening and patients are advised to restrict their fluid intake to less than 1.5 to 2 L/day. Assessments of symptoms (thirst and polyuria), urine osmolality, and serum sodium (obtained as "stat") are made twice daily. Careful monitoring during the trial of desmopressin is essential to promptly detect the development of hyponatremia. Thus, this trial should be performed in an outpatient setting <strong>only</strong> if the patient can reliably report symptoms and adhere to frequent monitoring. If there are any concerns that the patient cannot be carefully monitored, the trial of desmopressin should be performed as an inpatient.</p><p>The trial of <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> is interpreted as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with partial AVP-D, the polyuria and polydipsia will reverse, the urine will become concentrated and, if the patient was adherent to fluid restriction, the serum sodium should remain normal (although mild hyponatremia may develop, depending upon the level of fluid restriction). (See  <a class="medical medical_review" href="/d/html/2313.html" rel="external">"Arginine vasopressin deficiency (central diabetes insipidus): Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with primary polydipsia, <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> will not relieve the thirst, although the urine will be concentrated and, because of persistent water intake, the patient can become hyponatremic.</p><p></p><p>An alternative to performing a therapeutic trial of <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> is to measure plasma copeptin levels after infusing hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> to stimulate ADH release. However, copeptin assays are not yet commercially available in many regions, including in the United States.</p><p>Copeptin is the C-terminal glycoprotein moiety of the AVP prohormone and therefore a surrogate marker of ADH [<a href="#rid19">19,33</a>]. To distinguish central DI from primary polydipsia, hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> is infused to raise the serum sodium to &gt;145 mEq/L, at which point plasma copeptin is measured [<a href="#rid20">20</a>]. If reliable assays are available, the diagnosis is made as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>AVP-D is diagnosed if the plasma copeptin is ≤4.9 pmol/L.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary polydipsia is diagnosed if the plasma copeptin is &gt;4.9 pmol/L.</p><p></p><p>The study that reported this threshold copeptin level of 4.9 pmol/L infused hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> to raise the serum sodium concentration to &gt;150 rather than &gt;145 mEq/L [<a href="#rid20">20</a>]. However, the UpToDate authors and editors of this topic are concerned about the safety of raising the serum sodium concentration to this level and instead suggest that the target serum sodium during hypertonic saline infusion should be &gt;145 mEq/L. If the copeptin level is close to 4.9 pmol/L, there will still be some uncertainty about the diagnosis. If this occurs, the test can either be repeated (with a target serum sodium &gt;150 mEq/L) or a carefully supervised therapeutic trial of <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> can be used to distinguish between primary polydipsia and partial AVP-D.</p><p>If plasma copeptin levels are unavailable, <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> (ADH) levels should be measured on plasma samples collected both at baseline and after water deprivation or hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> infusion (but prior to the administration of <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a>) [<a href="#rid28">28,34</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>If there is an increase in plasma ADH in response to the rising plasma osmolality, AVP-D is excluded.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If there is an appropriate elevation in urine osmolality as ADH secretion is increased, AVP-R is excluded.</p><p></p><p>However, measurement of ADH concentrations may be misleading for several reasons [<a href="#rid35">35</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The commercially available assays for both plasma and urine ADH are not very sensitive, especially in the range below 3 pg/mL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ADH in the circulation is largely bound to platelets, and, without special handling of the specimen, falsely high and falsely low levels can be seen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ADH is unstable in isolated plasma, even when stored at -20°C so that send-out assays may be unreliable. Even highly sensitive assays may be misleading in patients with primary polydipsia since chronic overhydration can cause partial suppression of ADH release, mimicking the pattern in AVP-D [<a href="#rid32">32</a>].</p><p></p><p>Urinary assays have been suggested since the ADH concentration is higher in urine and the plasma separation issues may not apply. However, there are few data to support this approach.</p><p class="headingAnchor" id="H3215142958"><span class="h3">Patients with hypernatremia</span></p><p class="headingAnchor" id="H1410354891"><span class="h4">Differentiating solute diuresis from an arginine vasopressin disorder</span><span class="headingEndMark"> — </span>Hypernatremic patients with polyuria have either an <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> disorder, a solute diuresis, or, in some patients, both disorders. Hypernatremia rarely occurs unless such patients have no access to water or have impaired thirst, since the response to thirst should lead to correction of the water deficit. (See  <a class="medical medical_review" href="/d/html/2376.html" rel="external">"Etiology and evaluation of hypernatremia in adults"</a>.)</p><p>Primary polydipsia is not a consideration, because such patients will be normonatremic or hyponatremic.</p><p>Differentiating solute diuresis from an <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> disorder in hypernatremic patients with polyuria depends upon the urine osmolality:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypernatremic patients with a urine osmolality &gt;600 mosmol/kg have a solute diuresis. However, such patients may also have a component of either AVP-D or AVP-R.</p><p></p><p class="bulletIndent1">If infusion of dilute fluids to treat the hypernatremia does not produce a substantial decrease in the urine osmolality, then an osmotic diuresis is likely to be solely responsible for both the polyuria and hypernatremia. (See  <a class="medical medical_review" href="/d/html/2376.html" rel="external">"Etiology and evaluation of hypernatremia in adults", section on 'Osmotic diuresis'</a>.)</p><p></p><p class="bulletIndent1">However, if infusion of dilute fluids to correct the hypernatremia results in a decline in urine osmolality to &lt;600 mosmol/kg before the serum sodium concentration falls below 145 mEq/L, then a component of AVP-D or AVP-R in addition to a solute diuresis should be suspected. If the urine osmolality declines to &lt;300 mosmol/kg, before the serum sodium concentration falls below 145 mEq/L, then a diagnosis of either AVP-D or AVP-R can be made. In such patients, the history and the response to exogenous <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> can help classify the type of <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> disorder. (See <a class="local">'Classification of the arginine vasopressin disorder in hypernatremic patients'</a> below and <a class="local">'Clues from the history'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypernatremic patients with an intermediate urine osmolality of 300 to 600 mosmol/kg may have a component of both an <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> disorder and a solute diuresis. If the total daily osmolar output is &gt;1000 mosmol (calculated as the urine osmolality x the 24-hour urine volume), then a solute diuresis is present. Patients with total daily osmolar outputs &lt;900 mosmol have either AVP-D or AVP-R. In such patients, the history and the response to exogenous <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> can help classify the type of arginine vasopressin disorder. (See <a class="local">'Classification of the arginine vasopressin disorder in hypernatremic patients'</a> below and <a class="local">'Clues from the history'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypernatremic patients with a low urine osmolality of less than 300 mosmol/kg have either AVP-D or AVP-R. The history and the response to exogenous <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> can help classify the type of <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> disorder. (See <a class="local">'Classification of the arginine vasopressin disorder in hypernatremic patients'</a> below and <a class="local">'Clues from the history'</a> below.)</p><p></p><p class="headingAnchor" id="H2399624368"><span class="h4">Classification of the arginine vasopressin disorder in hypernatremic patients</span><span class="headingEndMark"> — </span>In patients with an <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> disorder, no cognitive impairment, and access to fluids, true hypernatremia should not occur, because the initial loss of water stimulates thirst, resulting in an increase in intake to match the urinary losses  (<a class="graphic graphic_figure graphicRef65195" href="/d/graphic/65195.html" rel="external">figure 2</a>). Thus, hypernatremia is seen primarily in patients who cannot experience thirst normally (eg, patients with impaired mental status, critical illness, or adipsia) or who cannot respond to thirst normally (eg, patients with physical constraints, young children who require others to provide fluid intake). (See  <a class="medical medical_review" href="/d/html/2376.html" rel="external">"Etiology and evaluation of hypernatremia in adults", section on 'The importance of thirst'</a>.)</p><p>The diagnostic approach to hypernatremic patients with an <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> disorder is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Adults with a urine osmolality &lt;300 mosmol/kg who are cognitively intact, have unlimited access to fluids, but who lack thirst have adipsic diabetes insipidus.</p><p></p><p class="bulletIndent1">Adipsic diabetes insipidus is usually due to a central lesion that impairs both thirst and release of ADH, thereby causing a water diuresis and hypodipsia or adipsia; in this setting, the plasma sodium concentration can exceed 160 mEq/L [<a href="#rid36">36</a>]. Adipsic diabetes insipidus is associated with significant morbidity including obesity, sleep apnea, venous thrombosis during episodes of hypernatremia, thermoregulatory dysfunction, seizures, and significant mortality [<a href="#rid37">37</a>]. Adipsic diabetes insipidus is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2376.html" rel="external">"Etiology and evaluation of hypernatremia in adults", section on 'Adipsic diabetes insipidus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polyuric infants with hypernatremia and urine osmolality &lt;300 mosmol/kg typically have hereditary AVP-R. Hypernatremia during the first year of life is a common feature in such patients. The intense and constant thirst of these young children is often not understood by adults, particularly if this is the first affected family member due to a de novo mutation or if an X-linked mutation has passed unrecognized through asymptomatic females [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In other patients, we generally give <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> (10 mcg by nasal insufflation or 2 to 4 mcg subcutaneously or intravenously) and judge the response by monitoring the urine osmolality every 30 minutes over the next two hours:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complete AVP-R – No elevation in urine osmolality and the urine osmolality is &lt;300 mosmol/kg</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Partial AVP-R – A small (up to 45 percent) elevation in urine osmolality to a level that remains &lt;300 mosmol/kg</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complete AVP-D – A rise in urine osmolality of more than 100 percent</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Partial AVP-D – An increase in urine osmolality of 15 to 50 percent to a level &gt;300 mosmol/kg</p><p></p><p class="headingAnchor" id="H484747423"><span class="h3">Patients with hyponatremia</span><span class="headingEndMark"> — </span>A low plasma sodium concentration in a polyuric patient is almost always indicative of water overload due to primary polydipsia. Such patients will have a low urine osmolality (eg, less than one-half the plasma osmolality).</p><p>If the patient has hyponatremia and a high, rather than low, urine osmolality, then an osmotically active substance, such as glucose or <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a>, is present causing both hyperosmolar hyponatremia and osmotic diuresis. Hyperglycemia is simple to diagnose and should be obvious, and infusion of mannitol should be apparent from the history. (See <a class="local">'Hyperglycemia or another obvious osmotic diuresis'</a> above.)</p><p class="headingAnchor" id="H2167360431"><span class="h3">Clues from the history</span></p><p class="headingAnchor" id="H7"><span class="h4">Rapidity of onset of polyuria</span><span class="headingEndMark"> — </span>The patient (or their parent or caregiver) should be questioned about the rate of onset of the polyuria. In the majority of cases of hereditary AVP-R, severe polyuria (with risk of dehydration and hypernatremia) manifests during the first week of life. In familial AVP-D (usually an autosomal dominant disease), polyuria may present after the first year of life, sometimes in young adulthood, due to preservation of function of the normal allele [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/d/html/2289.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Clinical manifestations and causes"</a> and  <a class="medical medical_review" href="/d/html/2373.html" rel="external">"Arginine vasopressin deficiency (central diabetes insipidus): Etiology, clinical manifestations, and postdiagnostic evaluation"</a>.)</p><p>In adults, the onset is usually abrupt in AVP-D ("I suddenly began urinating too much a few days ago") and almost always gradual in acquired AVP-R or primary polydipsia.</p><p>The new onset of nocturia in the absence of other causes of nocturia (eg, prostatic enlargement in men over 50 years of age or urinary tract infection in children) is often a first clue to an <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> disorder. The urine is normally most concentrated in the morning due to lack of fluid ingestion overnight; as a result, the first manifestation of a loss of concentrating ability is often nocturia.</p><p class="headingAnchor" id="H8"><span class="h4">Family history of polyuria or an arginine vasopressin disorder</span><span class="headingEndMark"> — </span>There are familial forms of both AVP-D and AVP-R. The defects in these disorders are due to mutations that impair ADH synthesis or the renal response to ADH; the latter defect is most often due to mutations in the <em>AVPR2</em> gene encoding the V2 receptor but can also result from mutations in the aquaporin-2 (water channel) gene [<a href="#rid39">39</a>]. A family history of polyuria is helpful both for diagnosis and to identify asymptomatic members of affected families who harbor the suspect allele. Thus, all families with a hereditary <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> disorder should have their molecular defect identified. (See  <a class="medical medical_review" href="/d/html/2289.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Clinical manifestations and causes"</a> and  <a class="medical medical_review" href="/d/html/2373.html" rel="external">"Arginine vasopressin deficiency (central diabetes insipidus): Etiology, clinical manifestations, and postdiagnostic evaluation"</a>.)</p><p class="headingAnchor" id="H2542534169"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109733.html" rel="external">"Society guideline links: Fluid and electrolyte disorders in adults"</a>.)</p><p class="headingAnchor" id="H169269725"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/17196.html" rel="external">"Patient education: Arginine vasopressin disorders (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and differential diagnosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Polyuria has generally been defined as a urine output exceeding 3 L/day in adults and 2 L/m<sup>2</sup> in children. It must be differentiated from the more common complaints of frequency or nocturia, which may not be associated with an increase in the total urine output. (See <a class="local">'Introduction and definition'</a> above and <a class="local">'Confirm the presence of polyuria'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Polyuria may be caused by a solute (osmotic) diuresis or a water diuresis  (<a class="graphic graphic_table graphicRef119681" href="/d/graphic/119681.html" rel="external">table 1</a>). Major causes of polyuria due to a solute diuresis include glucosuria (eg, in patients with uncontrolled diabetes mellitus), urea diuresis (eg, in patients with resolving acute kidney injury, and sodium diuresis (eg, in patients given larger volumes of intravenous <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>). (See <a class="local">'Solute (osmotic) diuresis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Primary polydipsia, <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> deficiency (AVP-D; previously called central diabetes insipidus), and arginine vasopressin resistance (AVP-R; previously called nephrogenic diabetes insipidus) are associated with an increase in water output and the excretion of a relatively dilute urine (ie, water diuresis)  (<a class="graphic graphic_table graphicRef119681" href="/d/graphic/119681.html" rel="external">table 1</a>). In primary polydipsia, the polyuria is an appropriate response to enhanced water intake, whereas the water loss is inappropriate with either AVP-D or AVP-R. (See <a class="local">'Water diuresis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation overview</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In some patients, the history and initial laboratory testing may clearly point to a specific osmotic diuresis, often making further evaluation unnecessary (eg, hyperglycemia and glucosuria). If unsure, the presence of an osmotic diuresis can be confirmed by a urine osmolality greater than 400 to 600 mosmol/kg and a total daily osmolar output &gt;1000 mosmol. (See <a class="local">'Hyperglycemia or another obvious osmotic diuresis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the etiology is unclear, the evaluation depends in part upon whether or not the patient has a normal serum sodium, hypernatremia, or hyponatremia  (<a class="graphic graphic_algorithm graphicRef119721" href="/d/graphic/119721.html" rel="external">algorithm 1</a>). (See <a class="local">'When the cause is not obvious'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Normonatremic patients</strong> – Normonatremic patients may have a solute diuresis, primary polydipsia, or an <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> disorder:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Normonatremic patients with a urine osmolality &gt;600 mosmol/kg have a solute (osmotic) diuresis. (See <a class="local">'Solute (osmotic) diuresis'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In normonatremic patients with an intermediate urine osmolality of 300 to 600 mosmol/kg, the total daily osmolar output should be calculated; if &gt;1000 mosmol, then a solute diuresis is present. However, if the total daily osmolar output is &lt;900 mosmol (a normal value), then the patient has a water diuresis due either to primary polydipsia or an <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> disorder. (See <a class="local">'Urine osmolality 300 to 600 mosmol/kg'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Normonatremic patients with a low urine osmolality of &lt;300 mosmol/kg have a water diuresis due either to primary polydipsia or an <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> disorder. (See <a class="local">'Urine osmolality &lt;300 mosmol/kg'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypernatremic patients</strong> – Hypernatremic patients with a urine osmolality &gt;600 mosmol/kg have a solute diuresis but may also have an <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> disorder. If infusion of dilute fluids to correct the hypernatremia results in a decline in urine osmolality to &lt;600 mosmol/kg before the serum sodium concentration falls below 145 mEq/L, then a component of AVP-D or AVP-R in addition to a solute diuresis should be suspected; if the urine osmolality declines to &lt;300 mosmol/kg before the serum sodium concentration falls below 145 mEq/L, then a diagnosis of either AVP-D or AVP-R can be made. Hypernatremic patients with a urine osmolality of 300 to 600 mosmol/kg should have the total daily osmolar output calculated to differentiate solute diuresis from an arginine vasopressin disorder (either AVP-D or AVP-R is the diagnosis if the total daily osmolar output is &lt;900 mosmol). Hypernatremic patients with a urine osmolality &lt;300 mosmol/kg have either AVP-D or AVP-R. (See <a class="local">'Patients with hypernatremia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hyponatremic patients</strong> – Hyponatremia in a polyuric patient is almost always indicative of water overload due to primary polydipsia. However, if the urine osmolality is high, then an osmotically active substance, such as glucose, is present causing both hyperosmolar hyponatremia and osmotic diuresis. (See <a class="local">'Patients with hyponatremia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific evaluation of a water diuresis (including the water restriction test)</strong> – In normonatremic patients with a water diuresis of unclear etiology, differentiating primary polydipsia from an <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> disorder requires further evaluation with water restriction (and/or hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> infusion) to achieve a goal plasma sodium concentration &gt;145 mEq/L  (<a class="graphic graphic_algorithm graphicRef131883" href="/d/graphic/131883.html" rel="external">algorithm 2</a>); this will stimulate vasopressin sufficiently to produce a maximally concentrated urine. The protocol for reaching this goal depends upon the age and reliability of the patient. (See <a class="local">'Goal of water restriction (or hypertonic saline)'</a> above and <a class="local">'Protocol in adults and adolescents'</a> above and <a class="local">'Protocol in infants and children'</a> above.)</p><p></p><p class="bulletIndent1">After a plasma sodium concentration &gt;145 mEq/L has been achieved, the subsequent evaluation depends upon the urine osmolality (see <a class="local">'Protocol in adults and adolescents'</a> above and <a class="local">'Protocol in infants and children'</a> above and <a class="local">'Judging the response to desmopressin'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the urine osmolality has reached a clearly normal value (above approximately 700 mosmol/kg), the diagnosis is primary polydipsia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the urine osmolality is &lt;700 mosmol/kg, we administer <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> (or, less commonly, aqueous <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a>) and judge the response. Determination of plasma copeptin or vasopressin levels is an alternative to desmopressin administration. However, assays for copeptin and vasopressin are infrequently available.</p><p></p><p class="bulletIndent1">In hypernatremic patients with an <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> disorder, water restriction is unnecessary. Hypernatremic adults with a urine osmolality &lt;300 mosmol/kg who are cognitively intact, have unlimited access to fluids, but lack thirst have adipsic diabetes insipidus. Polyuric infants with hypernatremia and urine osmolality &lt;300 mosmol/kg typically have hereditary AVP-R. In other patients, we give exogenous antidiuretic hormone (ADH; typically <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a>) and judge the response in order to distinguish between AVP-D and AVP-R. (See <a class="local">'Classification of the arginine vasopressin disorder in hypernatremic patients'</a> above.)</p><p></p><p class="bulletIndent1">Judging the response to <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> helps to differentiate primary polydipsia from an <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> disorder (in normonatremic patients) and to distinguish AVP-D from AVP-R (in normonatremic or hypernatremic patients) (see <a class="local">'Judging the response to desmopressin'</a> above and <a class="local">'Classification of the arginine vasopressin disorder in hypernatremic patients'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">Desmopressin</a> will more than double the urine osmolality (and generate an equivalent fall in urine output) in complete AVP-D and increase the osmolality to a lesser degree in partial AVP-D.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">Desmopressin</a> produces no or minimal elevation (ie, &lt;15 percent) in urine osmolality in complete AVP-R. A small (up to 45 percent) elevation in urine osmolality occurs in partial AVP-R. Although the directional change in partial AVP-R is similar to that seen with partial AVP-D, the absolute numbers are quite different. Patients with AVP-D usually achieve a urine osmolality of 300 mosmol/kg or higher after desmopressin, while patients with symptomatic acquired AVP-R typically have a persistently dilute urine with an osmolality that rises, but remains well below 300 mosmol/kg, after desmopressin.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Primary polydipsia will be associated with no response to <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a>, since endogenous release is intact. Maximum concentrating ability is frequently impaired in this disorder, resulting in a maximum urine osmolality that may reach 500 to 600 mosmol/kg, as compared with 800 mosmol/kg or more in normal subjects. This acquired defect appears to be due to two effects of chronic polydipsia and polyuria: partial wash out of the medullary interstitial gradient and downregulation of ADH release [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1">However, distinguishing between partial AVP-D and primary polydipsia may be difficult even when the test is performed properly. If the diagnosis remains uncertain (see <a class="local">'If water restriction is nondiagnostic'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We perform a three-day therapeutic trial of <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> (given in the evening) with assessments of symptoms (thirst and polyuria), urine osmolality, and serum sodium made twice daily. In patients with partial AVP-D, the polyuria and polydipsia will reverse, the urine will become concentrated, and the serum sodium should remain normal (although mild hyponatremia may develop if the patient does not restrict fluids). In patients with primary polydipsia, desmopressin will not relieve the thirst, although the urine will be concentrated and, because of persistent water intake, the patient can become hyponatremic.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An alternative to performing a therapeutic trial of <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> is to measure plasma copeptin levels (if available) after a plasma sodium &gt;145 mEq/L is attained (with water restriction or hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>)  (<a class="graphic graphic_algorithm graphicRef131884" href="/d/graphic/131884.html" rel="external">algorithm 3</a>). Copeptin is a surrogate marker of ADH. Partial AVP-D is diagnosed if the plasma copeptin is ≤4.9 pmol/L. Primary polydipsia is diagnosed if the plasma copeptin is &gt;4.9 pmol/L.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.748, 767.</li><li><a class="nounderline abstract_t">Weir MR, Januszewicz A, Gilbert RE, et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich) 2014; 16:875.</a></li><li><a class="nounderline abstract_t">Rondon-Berrios H, Tandukar S, Mor MK, et al. Urea for the Treatment of Hyponatremia. Clin J Am Soc Nephrol 2018; 13:1627.</a></li><li><a class="nounderline abstract_t">Gault MH, Dixon ME, Doyle M, Cohen WM. Hypernatremia, azotemia, and dehydration ue to high-protein tube feeding. Ann Intern Med 1968; 68:778.</a></li><li><a class="nounderline abstract_t">Howards SS. Post-obstructive diuresis: a misunderstood phenomenon. J Urol 1973; 110:537.</a></li><li><a class="nounderline abstract_t">Bishop MC. Diuresis and renal functional recovery in chronic retention. Br J Urol 1985; 57:1.</a></li><li><a class="nounderline abstract_t">Gibbons MD, Koontz WW Jr. Obstructive uropathy and nephrogenic diabetes insipidus in infants. J Urol 1979; 122:556.</a></li><li><a class="nounderline abstract_t">Smoyer WE. Medical management of postobstructive polyuria. Am J Dis Child 1991; 145:1345.</a></li><li><a class="nounderline abstract_t">Boyd SD, Raz S, Ehrlich RM. Diabetes insipidus and nonobstructive dilation of urinary tract. Urology 1980; 16:266.</a></li><li><a class="nounderline abstract_t">Ulinski T, Grapin C, Forin V, et al. Severe bladder dysfunction in a family with ADH receptor gene mutation responsible for X-linked nephrogenic diabetes insipidus. Nephrol Dial Transplant 2004; 19:2928.</a></li><li><a class="nounderline abstract_t">Shalev H, Romanovsky I, Knoers NV, et al. Bladder function impairment in aquaporin-2 defective nephrogenic diabetes insipidus. Nephrol Dial Transplant 2004; 19:608.</a></li><li><a class="nounderline abstract_t">Lopez-Garcia SC, Downie ML, Kim JS, et al. Treatment and long-term outcome in primary nephrogenic diabetes insipidus. Nephrol Dial Transplant 2020.</a></li><li><a class="nounderline abstract_t">Bockenhauer D, Bichet DG. Inherited secondary nephrogenic diabetes insipidus: concentrating on humans. Am J Physiol Renal Physiol 2013; 304:F1037.</a></li><li><a class="nounderline abstract_t">Blantz RC, Pelayo JC. A functional role for the tubuloglomerular feedback mechanism. Kidney Int 1984; 25:739.</a></li><li><a class="nounderline abstract_t">Schnermann J, Traynor T, Yang T, et al. Tubuloglomerular feedback: new concepts and developments. Kidney Int Suppl 1998; 67:S40.</a></li><li><a class="nounderline abstract_t">Christensen JH, Rittig S. Familial neurohypophyseal diabetes insipidus--an update. Semin Nephrol 2006; 26:209.</a></li><li><a class="nounderline abstract_t">Habiby R, Bichet DG, Arthus MF, et al. A Novel Form of Familial Vasopressin Deficient Diabetes Insipidus Transmitted in an X-linked Recessive Manner. J Clin Endocrinol Metab 2022; 107:e2513.</a></li><li><a class="nounderline abstract_t">Refardt J, Winzeler B, Meienberg F, et al. Empagliflozin Increases Short-Term Urinary Volume Output in Artificially Induced Syndrome of Inappropriate Antidiuresis. Int J Endocrinol 2017; 2017:7815690.</a></li><li><a class="nounderline abstract_t">Timper K, Fenske W, Kühn F, et al. Diagnostic Accuracy of Copeptin in the Differential Diagnosis of the Polyuria-polydipsia Syndrome: A Prospective Multicenter Study. J Clin Endocrinol Metab 2015; 100:2268.</a></li><li><a class="nounderline abstract_t">Fenske W, Refardt J, Chifu I, et al. A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus. N Engl J Med 2018; 379:428.</a></li><li><a class="nounderline abstract_t">Atila C, Monnerat S, Urwyler SA, et al. The effect of glucose dynamics on plasma copeptin levels upon glucagon, arginine, and macimorelin stimulation in healthy adults : Data from: Glucacop, Macicop, and CARGO study. Pituitary 2022; 25:636.</a></li><li><a class="nounderline abstract_t">Winzeler B, Cesana-Nigro N, Refardt J, et al. Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study. Lancet 2019; 394:587.</a></li><li><a class="nounderline abstract_t">Grandone A, Marzuillo P, Patti G, et al. Changing the diagnostic approach to diabetes insipidus: role of copeptin. Ann Transl Med 2019; 7:S285.</a></li><li><a class="nounderline abstract_t">de Fost M, Oussaada SM, Endert E, et al. The water deprivation test and a potential role for the arginine vasopressin precursor copeptin to differentiate diabetes insipidus from primary polydipsia. Endocr Connect 2015; 4:86.</a></li><li><a class="nounderline abstract_t">Fenske W, Allolio B. Clinical review: Current state and future perspectives in the diagnosis of diabetes insipidus: a clinical review. J Clin Endocrinol Metab 2012; 97:3426.</a></li><li><a class="nounderline abstract_t">Pedrosa W, Drummond JB, Soares BS, Ribeiro-Oliveira A Jr. A COMBINED OUTPATIENT AND INPATIENT OVERNIGHT WATER DEPRIVATION TEST IS EFFECTIVE AND SAFE IN DIAGNOSING PATIENTS WITH POLYURIA-POLYDIPSIA SYNDROME. Endocr Pract 2018; 24:963.</a></li><li><a class="nounderline abstract_t">Miller M, Dalakos T, Moses AM, et al. Recognition of partial defects in antidiuretic hormone secretion. Ann Intern Med 1970; 73:721.</a></li><li><a class="nounderline abstract_t">Zerbe RL, Robertson GL. A comparison of plasma vasopressin measurements with a standard indirect test in the differential diagnosis of polyuria. N Engl J Med 1981; 305:1539.</a></li><li><a class="nounderline abstract_t">Fujiwara TM, Bichet DG. Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol 2005; 16:2836.</a></li><li><a class="nounderline abstract_t">Bichet DG. GENETICS IN ENDOCRINOLOGY Pathophysiology, diagnosis and treatment of familial nephrogenic diabetes insipidus. Eur J Endocrinol 2020; 183:R29.</a></li><li class="breakAll">Robertson GL. Diseases of the posterior pituitary. In: Endocrinology and Metabolism, Felig D, Baxter JD, Broadus AE, et al (Eds), McGraw-Hill, New York 1981. p.251.</li><li><a class="nounderline abstract_t">Moses AM, Clayton B. Impairment of osmotically stimulated AVP release in patients with primary polydipsia. Am J Physiol 1993; 265:R1247.</a></li><li><a class="nounderline abstract_t">Winzeler B, Zweifel C, Nigro N, et al. Postoperative Copeptin Concentration Predicts Diabetes Insipidus After Pituitary Surgery. J Clin Endocrinol Metab 2015; 100:2275.</a></li><li><a class="nounderline abstract_t">Diederich S, Eckmanns T, Exner P, et al. Differential diagnosis of polyuric/polydipsic syndromes with the aid of urinary vasopressin measurement in adults. Clin Endocrinol (Oxf) 2001; 54:665.</a></li><li><a class="nounderline abstract_t">Szinnai G, Morgenthaler NG, Berneis K, et al. Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab 2007; 92:3973.</a></li><li><a class="nounderline abstract_t">McIver B, Connacher A, Whittle I, et al. Adipsic hypothalamic diabetes insipidus after clipping of anterior communicating artery aneurysm. BMJ 1991; 303:1465.</a></li><li><a class="nounderline abstract_t">Crowley RK, Sherlock M, Agha A, et al. Clinical insights into adipsic diabetes insipidus: a large case series. Clin Endocrinol (Oxf) 2007; 66:475.</a></li><li><a class="nounderline abstract_t">Arthus MF, Lonergan M, Crumley MJ, et al. Report of 33 novel AVPR2 mutations and analysis of 117 families with X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol 2000; 11:1044.</a></li><li><a class="nounderline abstract_t">Bockenhauer D, Bichet DG. Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus. Nat Rev Nephrol 2015; 11:576.</a></li></ol></div><div id="topicVersionRevision">Topic 2381 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.748, 767.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25329038" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30181129" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Urea for the Treatment of Hyponatremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4966815" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hypernatremia, azotemia, and dehydration ue to high-protein tube feeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4750897" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Post-obstructive diuresis: a misunderstood phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3971092" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Diuresis and renal functional recovery in chronic retention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/480505" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Obstructive uropathy and nephrogenic diabetes insipidus in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1669655" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Medical management of postobstructive polyuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7423704" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Diabetes insipidus and nonobstructive dilation of urinary tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15496575" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Severe bladder dysfunction in a family with ADH receptor gene mutation responsible for X-linked nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14767016" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Bladder function impairment in aquaporin-2 defective nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33367818" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Treatment and long-term outcome in primary nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23364801" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Inherited secondary nephrogenic diabetes insipidus: concentrating on humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6381854" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A functional role for the tubuloglomerular feedback mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9736251" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Tubuloglomerular feedback: new concepts and developments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16713494" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Familial neurohypophyseal diabetes insipidus--an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35137152" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A Novel Form of Familial Vasopressin Deficient Diabetes Insipidus Transmitted in an X-linked Recessive Manner.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29422914" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Empagliflozin Increases Short-Term Urinary Volume Output in Artificially Induced Syndrome of Inappropriate Antidiuresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25768671" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Diagnostic Accuracy of Copeptin in the Differential Diagnosis of the Polyuria-polydipsia Syndrome: A Prospective Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30067922" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35723775" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The effect of glucose dynamics on plasma copeptin levels upon glucagon, arginine, and macimorelin stimulation in healthy adults : Data from: Glucacop, Macicop, and CARGO study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31303316" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32016004" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Changing the diagnostic approach to diabetes insipidus: role of copeptin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25712898" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The water deprivation test and a potential role for the arginine vasopressin precursor copeptin to differentiate diabetes insipidus from primary polydipsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22855338" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clinical review: Current state and future perspectives in the diagnosis of diabetes insipidus: a clinical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30106630" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A COMBINED OUTPATIENT AND INPATIENT OVERNIGHT WATER DEPRIVATION TEST IS EFFECTIVE AND SAFE IN DIAGNOSING PATIENTS WITH POLYURIA-POLYDIPSIA SYNDROME.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5476203" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Recognition of partial defects in antidiuretic hormone secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7311993" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A comparison of plasma vasopressin measurements with a standard indirect test in the differential diagnosis of polyuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16093448" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Molecular biology of hereditary diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32580146" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : GENETICS IN ENDOCRINOLOGY Pathophysiology, diagnosis and treatment of familial nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32580146" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : GENETICS IN ENDOCRINOLOGY Pathophysiology, diagnosis and treatment of familial nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8285264" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Impairment of osmotically stimulated AVP release in patients with primary polydipsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25923040" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Postoperative Copeptin Concentration Predicts Diabetes Insipidus After Pituitary Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11380498" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Differential diagnosis of polyuric/polydipsic syndromes with the aid of urinary vasopressin measurement in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17635944" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1773159" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Adipsic hypothalamic diabetes insipidus after clipping of anterior communicating artery aneurysm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17371462" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clinical insights into adipsic diabetes insipidus: a large case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10820168" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Report of 33 novel AVPR2 mutations and analysis of 117 families with X-linked nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26077742" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
